Telomir Pharmaceuticals, Inc. Common Stock
- TELO
- NASDAQ
- Biotechnology
- Preclinical Small-Molecule Drugs
- TELOMIR-1 (Longevity/Novel Therapy)
$1.05
Today −0.92%Quote Oct 16, 2026, 08:00 PM UTC
−6.25%over the last month
Max drawdown −16.0%From 1-month high −16.0%3 months +14.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$77.3M
Quote Oct 16
Next earnings
Dec 2
Expected, not confirmed
Analyst target
$4.00
+281.0% from here
Floor
$1.04
1.0% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about TELOPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
2